Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency

• Prif Awduron: Baoshan Zhang (Awdur), Jason Gorman (Awdur), Young D. Kwon (Awdur), Amarendra Pegu (Awdur), Cara W. Chao (Awdur), Tracy Liu (Awdur), Mangaiarkarasi Asokan (Awdur), Michael F. Bender (Awdur), Tatsiana Bylund (Awdur), Leland Damron (Awdur), Deepika Gollapudi (Awdur), Paula Lei (Awdur), Yile Li (Awdur), Cuiping Liu (Awdur), Mark K. Louder (Awdur), Krisha McKee (Awdur), Adam S. Olia (Awdur), Reda Rawi (Awdur), Arne Schön (Awdur), Shuishu Wang (Awdur), Eun Sung Yang (Awdur), Yongping Yang (Awdur), Kevin Carlton (Awdur), Nicole A. Doria-Rose (Awdur), Lawrence Shapiro (Awdur), Michael S. Seaman (Awdur), John R. Mascola (Awdur), Peter D. Kwong (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

ABSTRACTAntibody CAP256-VRC26.25 targets the second hypervariable region (V2) at the apex of the HIV envelope (Env) trimer with extraordinary neutralization potency, although less than optimal breadth. To improve breadth, we linked the light chain of CAP256V2LS, an optimized version of CAP256-VRC26....